Table 1.
Characteristics of included studies.
| REferences | Sample size (E/C) | Treatment (E/C) | Course of treatment (months) | Outcome | Follow-up (months) | Number of shedding people (%) | Diagnostic criteria |
|---|---|---|---|---|---|---|---|
| Yu and Han (2007) | 34/33 | A/C | 3 | ② | – | 3 (4.48%) | Expert recommendation |
| Jiao (2011) | 30/30 | I/D | 2 | ② | – | 0 (0.00%) | Expert recommendation |
| Kong (2011) | 30/30 | I/D | 1.5 | ② | – | 0 (0.00%) | Expert recommendation |
| Li et al. (2012) | 50/50 | N/C | 3 | ② | – | 6 (6%) | CPT-2006 |
| Shao (2012) | 30/30 | G/C | 1.5 | ①② | – | 0 (0.00%) | CPT-2006 |
| Feng et al. (2013) | 24/24 | I/D | 1.5 | ②② | – | 0 (0.00%) | EC-2007 |
| Chen (2014) | 20/20 | G/C | 1 | ②② | – | 0 (0.00%) | CPT-2006 |
| Wang et al. (2014) | 30/30 | H/C | 3 | ① | – | 0 (0.00%) | Expert recommendation |
| Zhang (2014) | 30/30 | N/C | 1 | ②② | – | 0 (0.00%) | Expert recommendation |
| Zheng (2014) | 30/30 | H/C | 2 | ②② | – | 0 (0.00%) | Expert recommendation |
| Dong (2015) | 40/40 | G/C | 1 | ②② | – | 0 (0.00%) | CPT-2006 |
| Yang et al. (2015) | 36/36 | H/C | 3 | ① | – | 0 (0.00%) | GDT-2011 |
| Sun et al. (2016) | 40/40 | I/D | 3 | ① | – | 0 (0.00%) | CPT-2006 |
| Wang (2016) | 32/32 | A/C | 2 | ① | – | 3 (4.69%) | GDT-2011 |
| Wang et al. (2016) | 42/42/42 | A/H/C | 3 | ① | 3 | 7 (5.56%) | GDT-2011 |
| Liu and Xie (2017) | 60/30 | A/C | 1 | ①② | – | 0 (0.00%) | CPT-2006 |
| Sun (2017) | 33/33 | L/C | 1 | ①② | – | 6 (9.09%) | GDT-2011 |
| Wang et al. (2017) | 20/20 | A/C | 2 | ①② | – | 0 (0.00%) | VCIHS-2006 |
| Yu (2017) | 30/30 | I/D | 3 | ① | 3 | 5 (8.33%) | VCIHS-2006 |
| Zhao et al. (2017) | 17/17 | A/C | 3 | ①② | – | 0 (0.00%) | GDT-2011 |
| Li et al. (2018) | 30/30 | H/C | 1 | ① | – | 0 (0.00%) | GDT-2011 |
| Zhang (2018) | 30/30 | M/C | 1 | ① | – | 0 (0.00%) | ECM-2017 |
| Zhang and Li (2018) | 40/40 | B/C | 2 | ①② | – | 0 (0.00%) | MCIMP-2006 |
| Wang and Li (2018) | 64/64 | H/C | 2.5 | ①② | – | 0 (0.00%) | MCIDI-2004 |
| Luo et al. (2019) | 100/100 | G/C | 2 | ①② | 3 | 12 (6.00%) | Expert recommendation |
| Xu and Zhang (2019) | 56/38 | A/D | 2 | ① | – | 16 (17.02%) | DSM-V |
| Zhang et al. (2019) | 42/41/39 | A/K/F | 2 | ① | – | 17 (13.93%) | DSM-V |
| Meng et al. (2020) | 61/61 | I/D | 1 | ①② | – | 0 (0.00%) | Expert recommendation |
| Ni et al. (2020) | 31/30/31 | A/J/E | 2 | ① | – | 2 (2.17%) | EC-2007 |
| Yu et al. (2020) | 40/40 | I/D | 3 | ① | – | 0 (0.00%) | Expert recommendation |
| Bai et al. (2021) | 33/33 | I/D | 2 | ①② | – | 5 (7.58%) | CGD-2016 |
| Liu et al. (2021) | 34/34/34 | A/B/E | 1 | ① | – | 0 (0.00%) | CGD-2016 |
| Zhang (2021) | 35/35 | A/D | 1.5 | ①② | – | 2 (2.86%) | DSM-V |
E, experimental group; C, control group.
Treatment: A, manual acupuncture; B, electroacupuncture; C, nimodipine; D, donepezil hydrochloride; E, piracetam; F, herbal decoction; G, manual acupuncture plus electroacupuncture; H, manual acupuncture plus nimodipine; I, manual acupuncture plus donepezil hydrochloride; J, manual acupuncture plus piracetam; K, manual acupuncture plus herbal decoction; L, electroacupuncture plus nimodipine; M, warm acupuncture plus nimodipine; N, manual acupuncture plus electroacupuncture plus nimodipine.
Outcome: ①, Montreal Cognitive Assessment, MoCA; ②, Mini-Mental State Examination, MMSE.
Diagnostic criteria: CPT-2006, 2006 China Expert Consensus on Prevention and Treatment of Cognitive Dysfunction; EC-2007, 2007 Expert Consensus on Vascular Cognitive Impairment; GDT-2011, 2011 Guidance on Diagnosis and Treatment of Vascular Cognitive Impairment; VCIHS-2006, 2006 National Institute of Neurological Disorders and Stroke-Canadian stroke Network Vascular cognitive Impairment Harmonization standards; ECM-2017, 2017 Expert Consensus on The Management of Cognitive Disorders After Stroke; MCIMP-2006, 2006 Mild cognitive impairment (MCI)in medical practice; MCIDI-2004, 2004 Mild cognitive impairment diagnosis and intervention; DSM-V, Diagnostic and Statistical Manual of Mental Disorders-5th; CGD-2016, 2016 Chinese Guidelines for the Diagnosis of Vascular Mild Cognitive Impairment.